San Diego, CA, USA
Biotechnology · DeepTech · Health
1 - 10 employees
Origami Therapeutics is developing medicines that target and degrade disease-related proteins as a means of treating disease. They're a preclinical biopharmaceutical company determined to find innovative treatments for neurological disorders, starting with Huntington's disease. Their new protein degraders digest and eliminate disease-causing proteins by utilizing the body's natural protein disposal system. Neurodegenerative disorders such as Alzheimer's, Parkinson's, amyotrophic lateral sclerosis, and frontotemporal dementia are the target of its core programs.Something looks off?